|
1
|
Wils JA, Klein HO, Wagener DJT, et al:
Sequential high-dose methotrexate and fluorouracil combined with
doxorubicin – a step ahead in the treatment of advanced gastric
cancer: a trial of the european organization for research and
treatment of cancer gastrointestinal tract cooperative group. J
Clin Oncol. 9:827–831. 1991.PubMed/NCBI
|
|
2
|
Vanhoefer U, Rougier P, Wilke H, et al:
Final results of a randomized phase III trial of sequential
high-dose methotrexate, fluorouracil and doxorubicin versus
infusional fluorouracil and cisplatin in advanced gastric cancer: a
trial of the european organization for research and treatment of
cancer gastrointestinal tract cancer cooperative group. J Clin
Oncol. 18:2648–2657. 2000.PubMed/NCBI
|
|
3
|
Ohtsu A, Shimada Y, Shirao K, et al:
Randomized phase III trial of fluorouracil alone versus
fluorouracil plus cisplatin versus uracil and tegafur plus
mitomycin in patients with advanced gastric cancer: JCOG study
9205. J Clin Oncol. 21:54–59. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Webb A, Cunningham D, Scarffe JH, et al:
Randomized trial comparing epirubicin, cisplatin and fluorouracil
versus fluorouracil, doxorubicin and methotrexate in advanced
esophagogastric cancer. J Clin Oncol. 15:261–267. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dank M, Zaluski J, Barone C, et al:
Randomized phase III study comparing irinotecan combined with
5-fluorouracil and folinic acid to cisplatin combined with
5-fluorouracil in chemotherapy naive patients with advanced
adenocarcinoma of the stomach or esophagogastric junction. Ann
Oncol. 19:1450–1457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cunningham D, Starling N, Rao S, et al:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: V325 Study Group: Phase III study of docetaxel and cisplatin
plus fluorouracil compared with cisplatin and fluorouracil as
first-line therapy for advanced gastric cancer: a report of the
V325 Study Group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boku N, Yamamoto S, Fukuda H, et al:
Fluorouracil versus combination of irinotecan plus cisplatin versus
S-1 in metastatic gastric cancer: a randomized phase 3 study.
Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Narahara H, Iishi H, Imamura H, et al:
Randomized phase III study comparing the efficacy and safety of
irinotecan plus S-1 with S-1 alone as first-line treatment for
advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer.
14:72–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang YK, Kang WK, Shin DB, et al:
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: a
randomised phase III noninferiority trial. Ann Oncol. 20:666–673.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bang YJ, Cutsem E, Feyereislova A, et al:
ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chau I, Norman AR, Cunningham D, Waters
JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in
locally advanced and metastatic esophago-gastric cancer. Pooled
analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol. 22:2395–2403. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JG, Ryoo BY, Park YH, et al:
Prognostic factors for survival of patients with advanced gastric
cancer treated with cisplatin-based chemotherapy. Cancer Chemother
Pharmacol. 61:301–307. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee SS, Lee JL, Ryu MH, et al: Combination
chemotherapy with capecitabine (X) and cisplatin (P) as first line
treatment in advanced gastric cancer: experience of 223 patients
with prognostic factor analysis. Jpn J Clin Oncol. 37:30–37. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee J, Lim T, Uhm JE, et al: Prognostic
model to predict survival following first-line chemotherapy in
patients with metastatic gastric adenocarcinoma. Ann Oncol.
18:886–891. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahari D, Takashima A, Mizusawa J, et
al: Prognostic factors in Japanese patients with advanced gastric
cancer using the data from JCOG9912 study. Proc ASCO. abstract no.
4059. 2011.
|
|
20
|
Shirao K, Boku N, Yamada Y, Yamaguchi K,
Doi T, Takiuchi H, et al: Randomized phase III study of
5-fluorouracil continuous infusion (5FUci) versus methotrexate and
5-FU sequential therapy (MF) in gastric cancer with peritoneal
metastasis (JCOG0106). Proc ASCO. abstract no. 4545. 2009.
|
|
21
|
Ishigami H, Kitayama J, Kaisaki S,
Hidemura A, Kato M, Otani K, et al: Phase II study of weekly
intravenous and intraperitoneal paclitaxel combined with S-1 for
advanced gastric cancer with peritoneal metastasis. Ann Oncol.
21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matsubara J, Shimada Y, Takashima A, et
al: A phase i study of bolus 5-fluorouracil and leucovorin combined
with weekly paclitaxel (FLTAX) as first-line therapy for advanced
gastric cancer. Jpn J Clin Oncol. 38:540–546. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fuse N: Progression-free survival as
surrogate endpoint of overall survival in patients with
advanced/recurrent gastric cancer: individual patient data analysis
on 4,102 patients from 20 randomized trials. Proc JSCO: Plenaly.
1:2011.
|
